Work

671P LuMIERE: A phase I/II study evaluating safety, dosimetry, and preliminary activity of [177Lu]Lu-FAP-2286 in patients with advanced solid tumors

Year: 2024

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.737

Authors: J. McConathy, Y. Menda, J. Rodon, A.H. Goenka, R.H. Moy, S. Morse, A. Demange, P. Aimone, T.A. Hope

Institutions: University of Alabama at Birmingham, University of Iowa Health Care, The University of Texas MD Anderson Cancer Center, Mayo Clinic, Columbia University Irving Medical Center, Novartis (United States), Novartis (Switzerland), University of California, San Francisco

Language: English

Topic: Peptidase Inhibition and Analysis

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Prostate Cancer Foundation, Amgen, Eli Lilly and Company, Pfizer, Spectrum Pharmaceuticals, Alnylam Pharmaceuticals, Clovis Oncology, Progenics Pharmaceuticals, Incyte, Cardinal Health, Advanced Accelerator Applications, MacroGenics, Centene Corporation, Bayer HealthCare, European Society for Medical Oncology, Symphogen, National Institutes of Health, Loxo Oncology, National Cancer Institute

OpenAlex ID: W4402560041

FWCI: 2.913

Cites:

Cited by: 17

Related to: 10